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CONTEXT AND OBJECTIVES: The health technology assessment (HTA) process has been developed lo-
cally. The aim of this study was to describe, analyze and compare the opinions of participants in interna-
tional health economics symposia about the HTA process used in Brazil. 
DESIGN AND SETTING: Observational cross-sectional study at the 2006 and 2008 International Health 
Economics Symposia, in São Paulo.
METHODS: A structured questionnaire was applied. For the statistical analysis, the percentage distribution 
for each category was calculated, and variables were compared using tests for two-sample proportion 
hypotheses. 
RESULTS: Totals of 153 and 74 participants answered the 2006 and 2008 surveys, respectively. The re-
sponse rate was better for the 2006 survey (67.1%) than for the 2008 survey (31.8%). Most interviewees 
were between the ages of 30 and 49 years and were managers in the healthcare system. Most of them 
considered that the current HTA process was incomplete and unable to meet the needs of the healthcare 
system. They mentioned the government, academia and experts as the three main groups of people who 
should be involved in the process, and selected efficiency/effectiveness, safety and disease relevance as 
the three main criteria to be considered in the HTA process. There is a trend towards developing decentral-
ized regionalized HTA processes, with separate assessment and decision-making for the public and private 
systems. 
CONCLUSIONS: The HTA concept is well known. Healthcare system players feel that the process has 
methodological limitations. Additional surveys are needed to track the HTA process and its application 
in Brazil. 
reSUMO
CONTEXTO E OBJETIVOS: O processo de avaliação de tecnologias em saúde (ATS) tem sido desenvolvido 
localmente. O objetivo deste estudo foi descrever, analisar e comparar as opiniões dos participantes dos 
simpósios internacionais de economia da saúde sobre o processo de ATS utilizado no Brasil.
TIPO DE ESTUDO E LOCAL: Estudo observacional transversal, realizado nos Simpósios Internacionais de 
Economia da Saúde de 2006 e 2008, em São Paulo.
MÉTODOS: Um questionário estruturado foi aplicado. A análise estatística calculou a distribuição percen-
tual de cada categoria e comparou as variáveis com teste de hipóteses de proporções de duas amostras. 
RESULTADOS: Um total de 153 e 74 participantes responderam às pesquisas de 2006 e 2008, respectiva-
mente. A taxa de resposta foi melhor na pesquisa de 2006 (67,1%) do que na pesquisa de 2008 (31,8%). A 
maioria dos entrevistados estava entre 30 e 49 anos e era composta de gestores do sistema de saúde. A 
maioria considerou o atual processo de ATS incompleto e incapaz de satisfazer as necessidades do sistema 
de saúde. Entrevistados mencionaram o governo, academia e especialistas como os três principais grupos 
de pessoas que deveriam estar envolvidos no processo, e eficiência/efetividade, segurança e relevância 
da doença como os três principais critérios a serem considerados no processo de ATS. Existe a tendência 
de desenvolvimento de um processo de ATS descentralizado e regionalizado com avaliações e decisões 
separadas para o sistema público e privado.
CONCLUSÕES: O conceito ATS é conhecido. Os atores do sistema de saúde acham que o processo tem 
limitações metodológicas. Pesquisas adicionais são necessárias para acompanhar o processo de ATS e sua 
aplicação no Brasil.
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INTRODUCTION
The concept of health technology assessment (HTA) made its 
first international appearance in the 1960s, and has become an 
important decision-making tool for healthcare managers.1 Since 
the late 1980s, HTA has grown exponentially in Europe, North 
America, Australia, Latin America and Asia.2
In Brazil, HTA started in 1983, with a seminar in Brasilia 
hosted jointly by the Pan-American Health Organization/World 
Health Organization (PAHO/WHO) and the Brazilian govern-
ment. A number of aspects of HTA were discussed at this interna-
tional event: political issues such as the questionable effectiveness 
of various healthcare technologies, issues of cost and cost-effec-
tiveness and issues relating to technology transfer.3
Over the past six years, the HTA process has developed at 
an accelerated pace. In 2004, the Ministry of Health created its 
Department of Science and Technology (Departamento de Ciên-
cia e Tecnologia, DECIT) and approved the National Health Pol-
icy for Science, Technology and Innovation. In 2005, the Gen-
eral Coordination Office for Health Technology Assessment 
was created, with the mission of implementing, monitoring and 
disseminating HTA within Brazil’s Unified Healthcare System 
(Sistema Único de Saúde, SUS). In 2006, procedures for incor-
porating technology into SUS were created. In 2007, the Brazil-
ian Network for Health Technology Assessment (Rede Brasileira 
de Avaliação de Tecnologias em Saúde, REBRATS) was created 
to improve the government’s regulatory capacity, and its ability to 
define prioritization criteria and methodology for HTA studies.4-6 
In 2009, the Institute for Health Technology Assessment (Insti-
tuto de Avaliação de Tecnologia em Saúde, IATS) was created to 
develop, foster and disseminate HTA in Brazil, thereby provid-
ing technical information to help in decision-making process-
es.7 The first national HTA Guidelines for conducting healthcare 
economic evaluations in Brazil were published in 2009.8 In 2011, 
Brazil is going to host the annual Health Technology Assessment 
International (HTAi) meeting, in Rio de Janeiro.9
Since 2000, the São Paulo Center for Health Economics 
(Centro Paulista de Economia da Saúde, CPES), at the Univer-
sidade Federal de São Paulo (Unifesp), has organized an annual 
health economics symposium in the state capital. Public and 
private healthcare professionals, managers and administrators 
involved in healthcare decision-making participate in the event. 
Over the years, this symposium has become a major forum of 
discussion for the main players in the Brazilian healthcare sys-
tem, i.e. the Ministry of Health, state and municipal departments 
of health, service providers, healthcare insurers, regulatory agen-
cies, the healthcare pharmaceutical and device industry, patient 
associations and academics with links to research and teaching 
institutions.
Every year, the theme for discussion is selected based on its 
relevance and on the need for a discussion on the topic, among 
the various healthcare players. The last three symposia (2006, 
2007 and 2008) addressed HTA. Domestic and international par-
ticipants contributed through descriptions of the challenges that 
they face in HTA processes; the extent to which HTA has helped 
(or hindered) the decision-making process; and/or the extent to 
which HTA has in fact improved the healthcare system in their 
countries.
Although HTA has been incorporated at the federal level, 
Brazil’s regulatory framework is not yet complete. This means 
that HTA faces a major challenge with regard to its impact on 
how clinicians and healthcare system decision-makers think and 
act.3,10,11 Regulating healthcare technology has a direct effect on 
different groups (patients, government, funders, the industry, 
etc.), and each of these may or may not be favored as a result 
of the process.12 To initiate an awareness-raising process among 
these individuals, the first step is to understand their thoughts, 
feelings and expectations regarding HTA. 
OBJECTIVES
In spite of the importance of this topic, little is known about the 
opinions of Brazilian healthcare players regarding the HTA pro-
cess. To fill this gap, the aim of this study was to describe, ana-
lyze and compare the opinions of participants at the 2006 and 
2008 International Health Economics Symposia in relation to the 
HTA process. 
METHODS
Type of study, setting and participant sample
This was an observational cross-sectional study that used a struc-
tured questionnaire to investigate the opinions of a convenience 
sample from among the participants at the 2006 and 2008 Inter-
national Health Economics Symposia.
Tool
The questionnaire used for this survey was split into two parts:
Part 1 – Participant description. A group of seven questions 
was used to describe the sample of professionals participating at 
the International Health Economics Symposium, with regard to 
the following: gender, age, professional activity within the health-
care system, type of system (public or private) and main segment 
of professional activity;
Part 2 – Health Technology Assessment. This comprised six 
questions to ascertain the participants’ opinions on the process 
used to assess healthcare technology in Brazil: how it is done, 
who should participate, the criteria to be used and how the media 
and public opinion influence the process.
Procedure
The survey questionnaire was applied in a similar way during both 
the 2006 and the 2008 International Health Economics Symposia, 
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by means of a one-hour interactive session that was included as 
part of the symposium program. The coordinator of the interac-
tive session presented the purpose of the study and its intended 
use, and invited the audience to participate. Then, she explained 
in detail how to use the software (SunVote Professional Vot-
ing System, PVS-W52) to answer the questions. A few questions 
were used as examples to make the participants familiar with the 
use of the PVS-W52, which is an advanced two-way 2.4G radio 
frequency technology, with an easy-to-use keypad with 14 keys 
that is suitable for interactive sessions and audience response. It 
has multiple functions such as response feedback and number 
entering, which can be used to collect voters’ polling. The coordi-
nator read out each question, and both the question and the pos-
sible answerers were presented on a projection screen simultane-
ously. The interviewees were asked to give their personal opinion 
and not the opinion of the sector of activity that they represented. 
They were asked to press the keypad numbers corresponding to 
their answer, and had approximately one minute to accomplish 
this task. A number was assigned to each keypad, so that all the 
answers would be anonymous. The responses were sent to a collec-
tion center that automatically generated an Excel database, and the 
group results were immediately presented on a projection screen.
Data analysis
The participants’ responses were analyzed using the Stata 8.0 sta-
tistical software. The categorical variables were described in terms 
of the number of individuals and percentage in each of the cat-
egories. Variables were compared using tests for two-sample pro-
portion hypotheses. P values ≤ 0.05 were considered significant.
RESULTS
Table 1 describes the International Health Economics Sympo-
sium participants who responded to the survey in 2006 (n = 153) 
and 2008 (n = 74). The response rate was better for the 2006 sur-
vey (61.7%) than for the 2008 survey (31.8%), with a statistically 
significant difference between the groups (P = 0.0000). The per-
centage of women in the sample fell from 55.6% to 41.3% (P = 
0.0434). The percentage of participants in the age group between 
30 and 49 years fell from 65.3% to 48.6% (P = 0.0181). Nonethe-
less, most of the participants in both events were between the 
ages of 30 and 49 years. There were no differences in terms of 
what type of healthcare system they worked in. In terms of where 
they performed their professional activities, the number of pro-
fessionals linked to government or regulatory agencies increased 
considerably, from 24.0% to 42.6% (P = 0.0055), and the number 
linked to the healthcare pharmaceutical and device industry fell 
from 20.8% to 10.3% (P = 0.0011). Most of the respondents pri-
marily held managerial or administrative positions. The number 
of participants working as providers fell from 13.5% to 8.8% (P = 
0.0140), and the number of participants with links to research or 
teaching institutions increased (P = 0.0140).
The participants’ opinions about the HTA processes are sum-
marized in Table 2. At both symposia, the majority of the indi-
viduals (77.9% in 2006 and 86.8% in 2008) believed that the cur-
rent HTA processes used in the public and private healthcare 
systems were methodologically incomplete, insufficient in scope 
and unable to serve the current needs of the healthcare system. 
Around 3.1% in 2006 and 7.4% in 2008 stated that the processes 
Table 1. Demographics of the survey participants
NA: questions not asked at the 2006 symposium; *Values that did not show a 
statistically significant difference.
Symposium
2006
n (%)
2008
n (%)
P-value
Total number of participants in the 
symposium
228 (100) 233 (100)
Total number of participants in the survey
153 
(67.1)
74 (31.8) 0.0000
Gender
Female 84 (55.6) 26 (41.3) 0.0434
Male 67 (44.4) 37 (58.7) 0.0434
Age group (years)
Under 30 14 (9.3) 10 (14.3) *
Between 30 and 49 98 (65.3) 34 (48.6) 0.0181
Between 50 and 69 38 (25.3) 25 (35.7) *
Over 70 - 1 (1.4)
Healthcare system served by respondent
Public only 39 (27.7) 24 (36.4) *
Mostly public 10 (7.1) 5 (7.6) *
Almost equally divided between public 
and private
23 (16.3) 10 (15.2) *
Mostly private 25 (17.7) 7 (10.6) *
Private only 44 (31.2) 20 (30.3) *
Location of work
Government/regulatory agency 35 (24.0) 29 (42.6) 0.0055
University or research and teaching 
institution
10 (6.9) 10 (14.7) *
Hospital, laboratory, clinic or support unit 16 (11.0) 4 (5.9) *
Healthcare operators (self-managed, 
cooperatives, health insurance, group 
medicine)
32 (21.9) 13 (19.1) *
Healthcare pharmaceutical/device 
industry
45 (30.8) 7 (10.3) 0.0011
Industry or professional association 5 (3.4) 4 (5.9) *
Other entity not mentioned above 3 (2.0) 1 (1.5) *
Main role
Service provider/healthcare 20 (13.5) 6 (8.8) 0.0140
Teaching/research 10 (6.8) 12 (17.6) 0.0140
Administrator/manager 89 (60.1) 39 (57.4) *
Technician/support 25 (16.9) 9 (13.2) *
Council/healthcare committee 3 (2.0) 2 (2.9) *
Student 1 (0.7) -
Years working in the healthcare system
0-5 NA 14 (20.9)
6-10 NA 14 (20.9)
Over 11 NA 39 (52.7)
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were incomplete and broad in scope and unable to serve the 
current needs of the healthcare system. Only 1.4% in 2006 and 
5.9% in 2008 considered that the processes were complete, albeit 
insufficient in scope and unable to serve the current needs of the 
healthcare system.
With regard to who should be involved in the process of 
selecting the technologies that would be assessed, the responses 
were similar at the two symposia and mentioned the government 
and agencies, academic researchers and professional associations 
as the three main groups that should be involved, followed by the 
patients. In 2006, 10.8% of the respondents would include the lay 
public in the process used to prioritize technologies to be assessed, 
while in 2008, this number jumped to 23.4% (P = 0.0157). As 
expected, the groups consisting of consumer defense bodies and 
the healthcare pharmaceutical/device industry received the low-
est scores (8.9%-10.9% and 17.8%-9.4%, respectively).
Question
Symposium
2006
n (%)
2008
n (%)
P-value
1. In your opinion, is the HTA process currently used in our healthcare system (public or private):
Incomplete (methodologically), insufficient in scope (only for some technologies) and does not meet the needs 
of the healthcare system?
113 (77.9) 59 (86.8) *
Incomplete and insufficient in scope, but meets the current needs of the healthcare system? 5 (3.4) -
Incomplete and broad in scope; does not meet the current needs of the healthcare system? 19 (3.1) 5  (7.4) *
Incomplete and broad in scope; meets the current needs of the healthcare system? 2 (1.4) -
Complete but insufficient in scope; does not meet the current needs of the healthcare system? 2 (1.4) 4 (5.9) *
Complete and insufficient in scope, but meets the current needs of the healthcare system? - -
Complete and broad in scope, but does not meet the current needs of the healthcare system? 2 (1.4) -
Complete and broad in scope; meets the current needs of the healthcare system? 2 (1.4) -
2. Considering that any player in the healthcare system (including all citizens) can suggest which technologies 
should be assessed, who should participate in the process for selecting which technologies to assess? Mention 
three or fewer.
Lay public/society at large 17 (10.8) 15 (23.4) 0.0157
Patients/patient organizations 46 (29.3) 24 (37.5) *
Researchers/academics 96 (61.1) 41 (64.1) *
Government and agencies 107 (68.2) 49 (76.6) *
Professional associations/service providers 61 (38.9) 30 (46.9) *
Healthcare plan operators 40 (25.5) 11 (17.2) *
Supplies and products industry 28 (17.8) 6 (9.4) *
Consumer protection bodies 14 (8.9) 7 (10.9) *
3. What are the three most important criteria that should be applied to the HTA process?
Evidence of safety and risk relating to the technology 76 (52.4) 42 (63.6) *
Evidence of the effectiveness of the technology 117 (80.7) 56 (84.8) *
High cost of the technology and/or impact on the budget 67 (46.2) 22 (33.3) *
Relevance of the health problem/impact of the disease (high prevalence, high morbidity, high mortality) 124 (85.5) 51 (77.3) *
Lack of alternatives for the disease or condition 33 (22.8) 22 (33.3) *
Legal pressure and/or pressure from society 6 (4.1) 2 (3.0) *
Technology has never been assessed, even in other countries 6 (4.1) -
4. Taking both the public and the private healthcare systems into consideration, should HTA processes:
Provide a single assessment for both systems followed by a unified decision to incorporate made for both systems? 45 (32.1) 17 (26.6) *
Provide a single assessment for both systems followed by a decision to incorporate made by each system separately? 55 (39.3) 21 (32.8) *
Provide separate assessments for each system followed by a unified decision to incorporate made for both systems? 9 (6.4) 5 (7.8) *
Provide separate assessments and decisions to incorporate made for each system separately? 31 (22.1) 21 (32.8) *
5. Taking the regional differences in Brazil (population, needs and priorities) into consideration, should the (a) 
assessment process and (b) decision to incorporate technologies be:
(a) Centralized and (b) unified, and national in scope? 52 (37.1) 19 (28.4) *
(a) Centralized with (b) regional decisions? 63 (45.0) 29 (43.3) *
(a) Regionalized with (b) regional decisions? 25 (17.9) 19 (28.4) *
6. In your opinion, in general do the media and public opinion favor incorporating new technology in a manner 
that is:
Hasty and adequate 5 (3.4) 2 (2.9) *
Hasty and inadequate 106 (71.6) 48 (70.6) *
Timely and adequate 14 (9.5) 7 (10.3) *
Timely and inadequate 5 (3.4) 2 (2.9) *
Late and adequate 5 (3.4) 3 (4.4) *
Late and inadequate 13 (8.8) 6 (8.8) *
Table 2. Participants’ opinions about the Health Technology Assessment (HTA) process in Brazil
*Values that did not show a statistically significant difference.
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The interviewees selected evidence of effectiveness, relevance 
of the healthcare problem or impact on disease and evidence of 
risk and safety associated with use of the technology as the three 
main factors that should be used to prioritize which healthcare 
technologies to assess, followed by those relating to high cost of 
the technology and its impact on the budget (33.3%-46.2%) and 
lack of alternative for the disease or condition (22.8%-33.3%). 
Legal pressure and/or pressure from society received the lowest 
scores (3.0%-4.1%). The answers during the two symposia were 
similar.
With regard to the assessment process and decisions on 
whether to incorporate technologies into the public and private 
healthcare systems, opinions were divided during both sympo-
sia. The largest proportion of the 2006 participants (39.3%) felt 
that the assessment should be the same for both systems and that 
the decision to incorporate should be made by each system sep-
arately. Joint assessment and decisions to incorporate was the 
option selected by 32.1% of the participants, while 22.1% felt 
that it would be best if assessment and decisions to incorporate 
were handled separately by the public and private healthcare sys-
tems. In 2008, a large proportion of the participants (32.8%) also 
selected shared assessment and separate decisions to incorpo-
rate, but the same proportion of 32.8% selected separate assess-
ment and incorporation decisions, while 26.6% felt that a single 
assessment and decision to incorporate should be used for both 
systems. These findings may suggest that the centralized single 
assessment process followed by a unified decision for the two 
systems is moving towards separate assessments and decisions to 
incorporate for the two systems.
Taking the regional differences in Brazil into consideration, 
most of the participants (45.0% and 43.3%, respectively) at both 
symposia suggested that the assessment process should be cen-
tralized but that the decision to incorporate healthcare technolo-
gies should be regional. In 2006, 37.1% of them chose a central-
ized unified assessment process and a national decision regarding 
incorporation, followed by 17.9% that preferred regional pro-
cesses for both assessment and decisions to incorporate. In 2008, 
the scenario changed with a decrease in the percentage of those 
that preferred a centralized unified assessment process and an 
increase in the percentage of those that preferred regional pro-
cesses for both assessment and incorporation decisions.
At both symposia, the vast majority of the decision-makers 
(71.6% in 2006 and 70.6% in 2008) felt that the media and pub-
lic opinion currently favor incorporating new technologies in a 
manner that is both hasty and inadequate. Around 10% of them 
felt that the media and public opinion currently favor incorpo-
rating new technologies in a manner that is timely and adequate, 
and around 9% of them felt that the media and public opinion 
favored technological incorporation in a late and inadequate 
manner.
DISCUSSION
Health Economics Symposia are an important forum for cre-
ating awareness and teaching healthcare system players about 
the dilemmas and challenges of the HTA process. Above all, the 
forum has provided healthcare leaders and managers with an 
environment in which to discuss and reflect on the challenges 
that they face during the decision-making process. It has also 
promoted a dialogue among researchers and policymakers about 
how HTA can be a valuable tool for informing the decision-mak-
ing process in Brazil. 
In this study, we used volunteers who were available to us as 
our sample. The problem with this type of sample is that there is 
no evidence that such volunteers are representative of the popu-
lation. Nevertheless, our main objective here was to describe this 
particular group in an exploratory way. Interviewing these 227 
participants provided valuable insights into their opinions on 
the HTA process, even though this would not yield data on the 
proportion of healthcare players in the general population who 
might share these views. In general, the questionnaire responses 
on the HTA process were similar in 2006 and 2008. These two 
surveys may suggest rough estimates for the proportion of the 
population manifesting these opinions. When similar results are 
obtained repeatedly with different convenience samples, the like-
lihood that such results apply to the population is greater than 
when only a single convenience sample is used. Nevertheless, 
inferences based on such data must be made cautiously because 
of the possibility of hidden systematic bias.
Fewer participants provided responses in the 2008 (31.8%) 
survey than did in 2006 (61.7%). When people decline to par-
ticipate in a study, they may do so for reasons that could be very 
important for the study results. This is more likely to happen 
when the study calls for revelation of deeply personal or embar-
rassing information, which was not the case here. The only differ-
ence that might have affected the response rate was the timing of 
questionnaire application. In 2006, the survey was applied on the 
first day of the symposium, just after the main lecture of the day. 
In 2008, the survey was applied in the afternoon of the last day of 
the symposium. Many participants come from outside São Paulo 
and often return home before the end of the event. The lower 
response rate may indicate that the 2008 sample consisted of self-
selected participants, people who were motivated to participate, 
for some reason. Perhaps they were the ones more interested in 
the HTA process. 
The differences do not invalidate the results, which were 
quite similar for the two symposia. We are confident about the 
responses provided and believe that this study captured the 
respondents’ main opinions and made their position regarding 
the Brazilian HTA process clear. 
Increased participation by individuals with links to the gov-
ernment (P = 0.0055) and with links to research and teaching 
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institutions (P = 0.0140) may reflect increased attention to this 
topic among such individuals, and consequent willingness to par-
ticipate in the survey as they came to recognize the importance 
of the topic. It may also be an indication of the importance that 
both of these groups placed on the HTA process in Brazil. The 
majority of the assessments conducted to date have been com-
missioned and funded by the government, and have been carried 
out by researchers affiliated to local universities.
Regarding the question that explored the HTA process cur-
rently used in Brazil, the majority of the participants in both 
symposia considered that the process was methodologically 
incomplete. Similar findings were presented in the paper by 
Pichon-Riviere et al., in relation to whether the 15 key principles 
for guiding decisions on structure, methods, processes and use 
of HTA are relevant and useful in Latin America. Decision-mak-
ers in 18 Latin American countries, including Brazil, considered 
that Principle 5 (HTA should incorporate appropriate methods 
for assessing cost and benefits) and Principle 7 (A full society per-
spective should be considered when undertaking HTAs) were very 
relevant, but they stated that intermediate to large-magnitude 
“gaps” existed, i.e. mismatches between the importance of HTAs 
and their real application. This was taken to mean that there 
was a high level of perceived non-application of these method-
ological features in HTAs in Latin America, which also perhaps 
reflected an acceptable level of development of HTA capacity in 
the region.13
The interviewees’ opinion in the present study that the current 
HTA process was incomplete, insufficient in scope and unable 
to meet the needs of the healthcare system may be explained by 
the fact that the development of HTAs, although rapidly grow-
ing, is still embryonic in Brazil. Most of the assessments avail-
able through the website of DECIT, the Ministry of Health’s 
body responsible for coordinating HTA activities in Brazil, are 
systematic reviews5 and not methodologically complete HTAs. 
After summarizing the evidence, other methodological steps are 
necessary to finalize the assessment and make suitable recom-
mendations. An international study looking at the best way to 
incorporate effective technologies in 12 OECD (Organization for 
Economic Cooperation and Development) nations showed that 
only 14% of the HTAs could be categorized as broad assessments 
of medical technology.14 However, although neither complete 
nor broad, they seem to have presented decision-makers with the 
information that they need and to have met the goals of their 
healthcare systems.15 To illustrate with an example, the Ministry 
of Health’s Brazilian Bulletin for Health Technology Assessment 
showed that one systematic review on a product of uncertain 
clinical usefulness gave rise to a reduction in the annual budget 
requirement of around 800 million reais in 2005.6
The pace at which new knowledge is acquired and the con-
stant and growing offer of new technology, allied with the speed 
at which information now flows due to modern information and 
communication media, makes health technology assessment a 
true challenge to overcome. The need to develop local assessment 
processes and respect the characteristics of the healthcare system 
and resource availability pose an additional challenge. Not only 
is HTA a relatively new process within the international context, 
and one for which the methodology is still being developed, but 
also there is a need for qualified people to conduct and critically 
assess the process, results and recommendations so that HTA 
may guide the decisions made on behalf of the healthcare sys-
tem. There is a shortage of technically qualified personnel to per-
form HTA studies at the national level, which has led to a percep-
tion that the process is not broad enough, given that it leaves out 
numerous technologies. 
Thus, although the HTA process flow has existed since 2006, 
it is still seen as slow, unable to come to a resolution and unable 
to meet the needs of the healthcare system. The delays and the 
time required for assessments have also been the subject of criti-
cism in developed nations such as Canada, the UK and Austra-
lia, where there are well-established HTA agencies and the pro-
cess lasts around 11 to 18 months.16-18 In general, HTA evaluators 
and users recognize that the time that it takes to make a complete 
scientifically sound HTA is paradoxical to the urgent need for 
information in order to make a decision.19 The so-called techni-
cal time is considered to be unrealistic and incompatible with the 
political decision-making time. However, it is important to stress 
that the quality and scope of the HTA process can be impacted by 
the volume of resources and time available.20 The impact of HTAs 
depends on timely application in decision-making and subse-
quent implementation.21
In this study, the responses consistently pointed towards the 
government (Ministry and Departments of Health), research-
ers and professional associations as the three main groups that 
should be involved in the process for selecting and prioritizing 
technologies for assessment. However, in our 2008 survey, we 
noted that there was greater mention of including the lay pub-
lic, thereby reflecting what has already happened in other devel-
oped nations. For example, international agencies have included 
all players in their assessment process. In the UK, the National 
Center for Health and Clinical Excellence (NICE) allows patient 
groups to participate in all steps involved in developing a recom-
mendation, from designing the scope of the research to includ-
ing comments in the reports that are issued.22 Public interest in 
both the process and the prioritization of HTAs within decision-
making is clear, and a role for “the public” is widely promoted.23 
The Brazilian HTA policy will have to respond to the challenges 
of building public involvement into the bodies involved.
The ranking of the three most important elements for assess-
ing healthcare technology reflected the type of information that 
decision-makers felt was necessary. Between 80.7 and 84.8% 
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believed that effectiveness was an important factor, 77.3-85.5% 
believed that the relevance of the health problem was important 
and 52.4-63.6% felt that safety/risk elements were important. 
These were the same factors as listed in a survey of managers in 
charge of healthcare funding decisions in OECD countries. In 
that survey, 91% of the participants felt that safety was an impor-
tant element, 86% believed that effectiveness was important and 
81% felt that the relevance of the healthcare problem or disease 
burden was important.20 It is interesting to note that, although 
economic issues have always been present in national debates 
about healthcare funding and sustainability, the high cost of tech-
nology and its potential impact on the budget were not selected 
as one of the three main HTA criteria.
Given the connection between HTA and the bodies that for-
mulate health policy, the structure of the HTA process is molded 
by the type of healthcare system within which it takes place. In 
countries in which healthcare is primarily government funded 
(e.g. Sweden, Canada, Norway, UK and Spain), government 
agencies have been created for this purpose. On the other hand, 
in countries with private healthcare systems (such as the United 
States), HTA is handled by numerous individuals or groups 
linked to pension funds, healthcare funders or universities.15,24
In Brazil, although the healthcare system is mixed (the entire 
population of 190 million persons has the right to access SUS, 
while 41 million have access to the private healthcare system), 
the formal HTA structure is fundamentally linked to the public 
healthcare system. However, the split in responses to question 4 
may demonstrate that there remain questions regarding whether 
there should be a single assessment process for the two systems. 
From 2006 to 2008, in spite of an increase in the number of pro-
fessionals linked to the government or regulatory agencies that 
would potentially in charge of creating a public assessment body, 
and a decrease in the percentage of professionals from the phar-
maceutical and device industry, who might advocate different 
assessment processes for the public and supplemental healthcare 
systems, with less government interference, there was a slight 
increase in the number of responses selecting different assess-
ments and decisions to incorporate, for the two systems.
This also points towards the potential for tension between, 
on the one hand, the pharmaceutical and device industry and the 
providers of private healthcare who wish to offer the newest and 
best products and services, and thus prefer an HTA process that 
is quick, and, on the other hand, the SUS public policymakers 
who, because of lack of funds, must ensure that technologies are 
incorporated rationally so as to ensure the sustainability of the 
public healthcare system over time. 
CONCLUSION
The concept of HTA was well-known among leaders and deci-
sion-makers. Public and private healthcare system managers felt 
that the process had methodological limitations and did not ful-
fill the healthcare system needs. The leaders clearly revealed the 
main groups who should be involved and the most important 
criteria that should be applied to the HTA process. There was a 
trend towards developing decentralized regional HTAs, with dif-
ferent assessments and decisions to incorporate, for the public 
and private systems.
In spite of the challenges ahead for HTA, and moments of 
conflict among the various players, it is a tool that can contrib-
ute towards building an effective and efficient healthcare system. 
This study can help in focusing on factors that will make it pos-
sible to track the development of the HTA process and its imple-
mentation in Brazil.
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